Pharmacologic Substance
panobinostat Audio
[ pa-noh-bih-noh-stat ]
Brand Names:
Farydak
Effect:
Decreased Reverse Transcription to DNA
May Treat:
Multiple Myeloma
More Information:
ChemID; DrugBank; DailyMed; PDR
Definitions related to panobinostat:
  • A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.
    NCI
    U.S. National Cancer Institute, 2021
  • A drug being studied in the treatment of cancer. It blocks enzymes needed for cells to grow and divide and may kill cancer cells. Panobinostat may also prevent the growth of new blood vessels that tumors need to grow. It is a type of histone deacetylase inhibitor and a type of antiangiogenesis agent.
    NCI Dictionary of Cancer Terms
    U.S. National Cancer Institute, 2021
  • An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.
    NLM Medical Subject Headings
    U.S. National Library of Medicine, 2025
Try this search on: Farlex, Merriam-Webster, Oxford Dictionary, or Wordnik

This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.